What is Catalyst OrthoScience?
Founded in 2014 by orthopedic surgeon Dr. Steven Goldberg and headquartered in Naples, Florida, Catalyst OrthoScience is a pioneer in the development of advanced shoulder replacement technology. The company distinguishes itself through a focus on less invasive surgical procedures that aim to reduce post-operative complications while delivering a more natural-feeling joint replacement. By leveraging a growing portfolio of issued and pending patents, the firm provides surgeons with systems designed for high efficiency and reproducible clinical results. Its market position is defined by a commitment to preserving bone and soft tissue, a critical differentiator in the evolving field of musculoskeletal care. As the company scales, its technology is increasingly accessible to healthcare providers across the United States, setting a new standard for patient-centric orthopedic solutions.
How much funding has Catalyst OrthoScience raised?
Catalyst OrthoScience has raised a total of $40.2M across 5 funding rounds:
Debt
$350K
Debt
$713K
Other Financing Round
$20M
Stock/Share Issuance
$4.1M
Debt
$15M
Debt (2020): $350K with participation from PPP
Debt (2021): $713K led by PPP
Other Financing Round (2024): $20M supported by RC Capital, Bridge Bank, and Mutual Capital Partners
Stock/Share Issuance (2025): $4.1M, investors not publicly disclosed
Debt (2025): $15M backed by Mutual Capital Partners, Western Alliance Bank, and RC Capital
Key Investors in Catalyst OrthoScience
RC Capital
RC Capital is a growth equity firm focused on building high-potential healthcare companies by leveraging the interplay of medical devices, healthcare services, and healthcare IT.
Mutual Capital Partners
Mutual Capital Partners is a Cleveland-based venture capital fund that focuses on investing in early-stage software and medical device companies in the Midwest.
Western Alliance Bank
Western Alliance Bancorporation is a bank holding company providing deposit, lending, and treasury management services, with a dedicated segment for technology and innovation.
What's next for Catalyst OrthoScience?
With the successful closure of this latest funding round, Catalyst OrthoScience is poised to enter a new phase of operational scaling and market penetration. The strategic capital will likely be deployed to expand the company's sales infrastructure, enhance its R&D pipeline for next-generation surgical tools, and broaden its educational outreach to orthopedic surgeons nationwide. As the firm transitions into a more mature enterprise-level entity, the focus will remain on maintaining clinical excellence while scaling production to meet the rising demand for its specialized shoulder systems. Investors are expected to monitor the company's ability to capture additional market share from traditional, more invasive surgical methods, further validating the long-term viability of its innovative, patient-focused business model.
See full Catalyst OrthoScience company page
